The stock's performance looks even more underwhelming in the context of the 26.9% growth that the S&P 500 index managed to post across the year's trading. While the benchmark index managed to post ...
Vertex recently said the product may deliver more than $100 million in revenue in the 2025 full year. But it's important to ...
- More than 70 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; enrollment complete and regulatory submissions planned for late 2022- -Initiated and began dosing ...
Labroots invites you to the 4th Annual Event in the CRISPR Virtual Event Series! This event will continue the conversation of the abilities of CRISPR-based editing, next-gen editing tools, precision ...
In biotech and biopharma’s third-largest ever up-front development and commercialization deal, Crispr Therapeutics AG will receive an initial $900 million in an amended deal with Vertex ...
The global prime editing and CRISPR market size was US$ 3,194.2 million in 2021. The global prime editing and CRISPR market is forecast to grow to US$ 17,618.4 million by 2030 by registering a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback